ArticleApoptosis : an international journal on programmed cell death2025
TSLP mitigates post-infarction myocardial remodeling by promoting eosinophil recruitment and inhibiting JAK1-STAT5-mediated ferroptosis.
Article in Apoptosis : an international journal on programmed cell death, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Extracellular Vesicles in Myocardial Infarction: Dual Role in Ferroptosis Regulation and In Vivo Imaging.Diagnostics (Basel, Switzerland) · 2026Review
- STEAP4 drives immune dysregulation in myocardial infarction-NSCLC comorbidity.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Acute myocardial infarction (AMI) remains a leading cause of morbidity and mortality globally, often leading to heart failure due to excessive inflammation and fibrosis. Thymic stromal lymphopoietin (TSLP), a cytokine primarily involved in immune regulation, has recently been identified as a key player in cardiovascular health. However, its role in modulating inflammation and fibrosis after AMI is not fully understood. This study investigates how TSLP mediates anti-inflammatory effects and reduces fibrosis, ultimately improving heart function in a mouse model of AMI. We established a TSLP knockout mouse strain and performed left anterior descending (LAD) coronary artery ligation to create an AMI model. This was used to investigate the role of TSLP in eosinophil (EOS) recruitment and fibrosis alleviation. Additionally, EOS depletion, JAK-STAT pathway inhibition, and ferroptosis were employed to analyze potential mediating factors. The extent of cardiac tissue fibrosis was evaluated using histological staining. Inflammatory cytokine levels and EOS were assessed through ELISA and flow cytometry. Western blotting was conducted to detect proteins related to ferroptosis and the JAK-STAT pathway. TSLP deficiency significantly exacerbated myocardial remodeling in AMI mice, while TSLP treatment markedly reduced cardiac fibrosis following AMI, with a notable decrease in collagen deposition within the heart tissue. In Transwell assays, TSLP effectively recruited EOSs, and in vivo experiments demonstrated that TSLP promoted the resolution of acute-phase inflammation (within one week), a process that could be blocked by EOS depletion. TSLP promotes the resolution of post-infarction inflammation and inhibits fibrosis by recruiting EOSs to the heart. This highlights the potential of targeting the TSLP-EOS axis as a therapeutic strategy to improve cardiac function and reduce post-AMI complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.